Kiniksa director gifts 2,600 shares to donor fund

Kiniksa Pharmaceuticals International, plc (KNSA) director Barry D. Quart reported a bona fide gift of 2,600 Class A Ordinary Shares on 2026-08-19.

Rhea-AI Filing Summary

Kiniksa Pharmaceuticals International, plc (KNSA) director Barry D. Quart reported a bona fide gift of 2,600 Class A Ordinary Shares on 2026-08-19. The gift transferred shares at a reported price of $0.00 per share to a donor advised fund. Following this transaction, Quart directly holds 12,745 Class A Ordinary Shares.

Insider Trade Summary

2,600 shares gifted

Gift 1 txn

Insider Quart Barry D

Role Director

Type	Security	Shares	Price	Value
Gift	Class A Ordinary Share F1	2,600	$0.00	$0.00

Holdings After Transaction: Class A Ordinary Share — 12,745 shares (Direct)

Footnotes (1)

1. F1. This transaction involves a bona fide gift of securities from the reporting person to a donor advised fund.

Key Figures

Shares gifted: 2,600 Class A Ordinary Shares Transaction price per share: $0.00 per share Shares held after transaction: 12,745 Class A Ordinary Shares +1 more

4 metrics

Shares gifted 2,600 Class A Ordinary Shares Bona fide gift on 2026-08-19

Transaction price per share $0.00 per share Reported for the 2,600-share gift

Shares held after transaction 12,745 Class A Ordinary Shares Direct holdings following the gift

Gift transactions in this filing 1 gift; 2,600 shares Transaction summary giftCount and giftShares

Key Terms

bona fide gift, donor advised fund, Class A Ordinary Share

3 terms

bona fide gift financial

"This transaction involves a bona fide gift of securities"

A bona fide gift is a genuine, voluntary transfer of money, property, or benefits from one party to another made without expectation of repayment, services, or hidden conditions. Investors care because such gifts can affect company disclosures, related‑party transaction rules, tax treatment, and perceived conflicts of interest; think of it like someone giving you a present with no strings attached — but on a corporate scale, auditors and regulators need to verify it really is unconditional.

donor advised fund financial

"gift of securities from the reporting person to a donor advised fund"

A donor advised fund is a charitable savings account you fund with cash or assets (including stocks) that lets you take an immediate tax benefit while recommending when and which charities receive grants over time. Think of it like a dedicated piggy bank for giving: you get tax relief when you put money in, can avoid selling appreciated securities and triggering capital gains, and still control the timing and recipients of donations, which affects tax planning, portfolio decisions, and public giving signals.

Class A Ordinary Share financial

"security_title: Class A Ordinary Share"

A Class A ordinary share is a type of common stock a company issues that carries a specific set of rights—most often particular voting power, dividend terms, or transfer rules—distinct from other share classes. For investors it matters because those rights affect control over company decisions, how income is paid out, and how easy shares are to buy or sell; think of it like a tiered ticket that gives different access and influence at the same event.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What transaction did Barry D. Quart report in this Form 4 for KNSA?

Barry D. Quart reported a bona fide gift of 2,600 Class A Ordinary Shares of Kiniksa Pharmaceuticals International, plc on 2026-08-19. The filing states this was a gift to a donor advised fund and not a market sale or purchase.

How many KNSA shares did Barry D. Quart gift and at what price?

Barry D. Quart gifted 2,600 Class A Ordinary Shares of KNSA at a reported price of $0.00 per share. The Form 4 characterizes the transaction as a bona fide gift rather than a sale.

What are Barry D. Quart’s KNSA holdings after this reported gift?

After the reported gift, Barry D. Quart directly holds 12,745 Class A Ordinary Shares of Kiniksa Pharmaceuticals International, plc, as stated in the Form 4 under total shares following the transaction.

Was the KNSA Form 4 transaction a sale under a 10b5-1 trading plan?

No. The Form 4 identifies the transaction as a bona fide gift, not a sale, and the Rule 10b5-1 checkbox is not marked as an affirmative trading plan. The footnote explains the shares were gifted to a donor advised fund.

Who received the gifted KNSA shares from Barry D. Quart?

The Form 4 footnote states that the transaction involves a bona fide gift of KNSA securities from Barry D. Quart to a donor advised fund. The filing does not provide further detail about the fund.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/21/2026 - 04:35 PM Accepted by SEC EDGAR 08/21/2026 - 04:35 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Quart Barry D

(Last) (First) (Middle)

C/O KINIKSA PHARMACEUTICALS INT'L

105 PICCADILLY, SECOND FLOOR

(Street)

LONDON W1J 7NJ

(City) (State) (Zip)

UNITED KINGDOM

(Country)

2. Issuer Name and Ticker or Trading Symbol
Kiniksa Pharmaceuticals International, plc [ KNSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Ordinary Share	08/19/2026		G(1)		2,600	D	$0	12,745	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction involves a bona fide gift of securities from the reporting person to a donor advised fund.

	/s/ Douglas Barry, Attorney-in-Fact	08/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)